Granted Patent B2

US 12,709,614 · App. 19/271,548 · Granted Aug 18, 2026

Inventors: Bin Liang (Hong Kong, CN); Jinzi Jason Wu (Hong Kong, CN); Bailing Yang (Hong Kong, CN)

Assignee: ASCLETIS PHARMA (CHINA) CO., LIMITED

C07D471/04A61K31/437C07D519/00

Abstract

Claims (15)

1 . A method for treating a GLP-1R-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of compound 1,

or a pharmaceutically acceptable salt thereof;

wherein the GLP-1R-mediated disease or condition is selected from the group consisting of T1D (type 1 diabetes), T2DM (type 2 diabetes mellitus), hyperglycemia, weight management, chronic weight management, obesity, NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), Parkinson's disease and hypertension.

2 . The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt and a lithium salt.

3 . The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of

4 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is T1D (type 1 diabetes).

5 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is T2DM (type 2 diabetes mellitus).

6 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is hyperglycemia.

7 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is weight management.

8 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is chronic weight management.

9 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is obesity.

10 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is NAFLD (non-alcoholic fatty liver disease).

11 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is NASH (non-alcoholic steatohepatitis).

12 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is Parkinson's disease.

13 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is hypertension.

Priority Claims (10)

Continuity (7)

References Cited (340)